Those with preserved EF seemed to get more protection against HF events/CV death than those with reduced or unknown EF.
An oral GLP-1 medication may lower the risk of hospitalization or urgent visits for heart failure (HF), as well as CV death, in HF patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease, according to a subanalysis of the SOUL trial.
Compared with placebo, the risk of the composite outcome of time to first occurrence of HF hospitalization, urgent HF visit, or CV death was 22% lower over approximately 4 years of follow-up in those who had HF at baseline and took once-daily oral semaglutide (Rybelsus; Novo Nordisk). There was no reduction in this HF-oriented endpoint in those without HF at baseline.
Rodica Pop-Busui, MD, PhD (Oregon Health &…